Pharmacopeia — Pharmacopeia Drug Discovery — CIBC World Markets conference 2007
29 slides from Pharmacopeia's conference presentation, Apr 11, 2007

Slide 1: CIBC World Markets, April 11th, 2007
CIBC World Markets April 11th, 2007 Discovering excellence, driving clinical successTM

Slide 2: Forward-Looking Statements
Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which e

Slide 3: Value Drivers - Balanced Risk
Value Drivers - Balanced Risk Biopharmaceutical company Focused on cardiovascular and immunological diseases Deep pipeline of potential blockbusters 6 programs in active clinical development Leader in developing DARA – Phase 1 initiated 02/07 First-in-class dual-acting ARB and ERA for hypertension a

Slide 4: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

Slide 5: One of the Deepest Portfolios in Biotech
Inflammation PS386113 Asthma/Allergy* VLA-4 PS460644 Angiogenesis a v b 3/ a v b 5 Parkinson’s Adenosine A2A Rheumatoid/MS CCR1 Derm/Ocular JAK3 Topical Immuno/Inflam JAK3 Inflammation PS873266 Respiratory PS948115 Oncology PS241541 Cardiovascular DARA PS433540 Metabolic Disease PS522501 Oncology PS

Slide 6: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

Slide 7: CXCR2 Antagonists
CXCR2 Antagonists CXCR2 receptor expressed on neutrophils, monocytes and microvascular endothelial cells Multiple ligands – induced by IL-2, TNF a - including IL-8, GRO a attract immune cells to sites of inflammation Expected utility in inflammatory lung disease including COPD

Slide 8: CXCR2 Antagonists - COPD
CXCR2 Antagonists COPD includes chronic bronchitis and emphysema By 2010, expected to be 3rd leading cause of death in US In 2001 there were > 12 million diagnoses Current market = ~$9 billion CXCR2 antagonist in clinical development with Schering-Plough Active against biomarker at 50 mg in voluntee

Slide 9: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

Slide 10: p38 MAP Kinase Inhibitors Mechanism of Action
p38 MAP Kinase Inhibitors Mechanism of Action MK2 TNF a IL-1 RA – anti IL-1 Kineret Expected to block the pro-inflammatory effects of TNF a , IL-1 b , IL-6 Expected utility in RA, COPD, Psoriasis & IBD

Slide 11: p38 MAP Kinase Inhibitors
p38 MAP Kinase Inhibitors p38 kinase inhibitors for inflammatory diseases RA target population of 2.1 million patients Current RA market $5.6B in US alone PS540466 approaching Phase 2 Well tolerated in multiple Phase 1 trials Currently in RA patients receiving methotrexate Back up compound entered P

Slide 12: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

Slide 13: DARA – First-in-class
DARA – First-in-class DARA combines the properties of two marketed product classes Angiotensin II (Type 1) receptor blockers (ARBs) ETA selective endothelin receptor antagonists (ERAs) DARA could improve treatment of several cardiovascular diseases Dual Acting Angiotensin and Endothelin Receptor Ant

Slide 14: ARB + ERA = Synergistic Combination
ARB + ERA = Synergistic Combination Angiotensin II and Endothelin 1 Vasoconstriction Tissue proliferation and fibrosis Inflammation Preclinical Results - Hypertension Potent blockade of endothelin and angiotensin by oral route Potent BP lowering in two preclinical models predictive of activity in hy

Slide 15: PS433540 – Potent as ARB and ERA
PS433540 – Potent as ARB and ERA PS-433540 (DARA) 1.4 > 10,000 BMS-19384 > 10,000 2 Irbesartan (Avapro) Endothelin IC50 (nm, human) Angiotensin IC50 (nm, human) Compound Irbesartan(Avapro®) AT1 antagonist PS-433540 (DARA) AT1 and ETA antagonist BMS-193884 ETA antagonist Angiotensin group Endothelin

Slide 16: PS433540 – Antihypertensive Activity
PS433540 reduces blood pressure more than Irbesartan (Avapro) at 30 and 100 mmol/kg Effect of Irbesartan and PS433540 on Mean Arterial BP in Spontaneously Hypertensive Rats (SHR) PS433540 – Antihypertensive Activity PS433540

Slide 17: New Treatment Options
New Treatment Options Antihypertensive effect of PS433540 would support potential in hypertension and diabetic kidney disease Opportunity for DARA to be an attractive option in hypertension and kidney disease Combine ARB and ERA activity in a single compound, once-a-day pill Avoid polypharmacy typic

Slide 18: Early Clinical Evaluation
Early Clinical Evaluation Phase 1 Safety and Pharmacology in Healthy Subjects Establish Safety SAD (Single Ascending Dose) – up to 6 dose levels MAD (Multiple Ascending Dose) – up to 4 dose levels Confirm Dual Activity Mechanism Angiotensin Challenge in Healthy Volunteers Endothelin Challenge in Hea

Slide 19: Single Ascending Dose Study Complete
Single Ascending Dose Study Complete Double-blind, randomized, placebo-controlled study to assess safety and tolerability after oral administration of single escalating doses to healthy male subjects Protocol Outline 7 groups – placebo, 20, 50, 100, 250, 500, 1000 mg 8 subjects per cohort – six PS43

Slide 20: DARA Development Schedule
DARA Development Schedule Complete data and material transfer from BMS 2Q-06 Synthesis of 2 Kg GMP of active ingredient (API) 3Q-06 Pre-IND meeting with FDA 08/15/06 3Q-06 Submit IND 12/28/06 1Q-07 ‘First in man’ dosing 02/13/07 1Q-07 Complete AII challenge study Mid-07 Complete ET challenge study 3

Slide 21: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

Slide 22: Strategic Partnerships
Strategic Partnerships Late stage optimization programs Upfront $15 million technology access fee Up to $35 million per program in milestones Double-digit royalties Builds portfolio and financial runway Pharmacopeia prosecutes Phase 1 and Phase 2 Non-dilutive tranched funding - $15 million Up to $83

Slide 23: Strategic Partnerships - Wyeth JAK3 Alliance
Strategic Partnerships Alliance to develop and commercialize JAK3 Inhibitors for Immunological and Inflammatory Diseases Upfront payment for discovery phase program - $5 million Up to $9MM in research funding over 3 years Up to $175MM in preclinical, clinical and commercialization milestones Double-

Slide 24: Strategic Partnerships - Organon Alliance
Strategic Partnerships New Alliance to discover and develop candidates with an option to co-commercialize therapeutic products Upfront payment for discovery collaboration - $15 million Research funding over 5 years - $20 million Buy-up option to co-develop and co-commercialize Preclinical, clinical

Slide 25: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

Slide 26: Financial Summary
Financial Summary For the year ended December 31st, 2006 $16.9 million in net revenue $ 27.8 million in net loss (including $2.0 million non-cash charge) Cash, Cash Equivalents and Marketable Securities $46.1 million as of December 31, 2006 $20 million upfront payments from Wyeth and Organon in 1Q-0

Slide 27: Stock Information
Stock Information Stock Exchange: NASDAQ Stock Symbol: PCOP Shares Outstanding (03/09/2007): 21.3 million 52- Week Range: $3.56 - $6.51 Daily Trading Volume (04/05/2007)*: >80,000 shares Market Capitalization (04/05/2007): ~ $125 million Enterprise Value**: ~ $60 million *Trailing 30-day average **C

Slide 28: Pharmacopeia Today
Pharmacopeia Today DARA Phase 1 clinical development on-going First-in-class approach to significant markets Hypertension Diabetic Nephropathy Partnered clinical programs advancing CXCR2 antagonist in Phase 2 for COPD (partnered with Schering-Plough) p38 kinase inhibitor for inflammatory disease – a

Slide 29: Discovering excellence, driving clinical success
Discovering excellence, driving clinical successTM
Source: SEC EDGAR · 8-K filed Apr 11, 2007
More decks from Pharmacopeia Inc
Pharmacopeia — Merger or Acquisition (November 2008)34 slides · Nov 3, 2008
The Oppenheimer 19th Annual Healthcare Conference (November 2008)33 slides · Nov 3, 2008
Ligand Pharmaceuticals — Merger or Acquisition (September 2008)18 slides · Sep 24, 2008
BMO Capital Markets 7th Annual Focus on Healthcare Conference 200822 slides · Aug 5, 2008
Investor Presentation (May 2008)36 slides · May 19, 2008
Investor Presentation (May 2008)11 slides · May 16, 2008